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Abstract: Osteoclast differentiation and activity are controlled by two essential cytokines, macrophage
colony-stimulating factor (M-CSF) and the receptor activator of nuclear factor-κB ligand (RANKL).
Rab11A GTPase, belonging to Rab11 subfamily representing the largest branch of Ras superfamily of
small GTPases, has been identified as one of the crucial regulators of cell surface receptor recycling.
Nevertheless, the regulatory role of Rab11A in osteoclast differentiation has been completely unknown.
In this study, we found that Rab11A was strongly upregulated at a late stage of osteoclast differentiation
derived from bone marrow-derived macrophages (BMMs) or RAW-D murine osteoclast precursor
cells. Rab11A silencing promoted osteoclast formation and significantly increased the surface levels
of c-fms and receptor activator of nuclear factor-κB (RANK) while its overexpression attenuated
osteoclast formation and the surface levels of c-fms and RANK. Using immunocytochemical staining
for tracking Rab11A vesicular localization, we observed that Rab11A was localized in early and late
endosomes, but not lysosomes. Intriguingly, Rab11A overexpression caused the enhancement of
fluorescent intensity and size-based enlargement of early endosomes. Besides, Rab11A overexpression
promoted lysosomal activity via elevating the endogenous levels of a specific lysosomal protein,
LAMP1, and two key lysosomal enzymes, cathepsins B and D in osteoclasts. More importantly,
inhibition of the lysosomal activity by chloroquine, we found that the endogenous levels of c-fms
and RANK proteins were enhanced in osteoclasts. From these observations, we suggest a novel
function of Rab11A as a negative regulator of osteoclastogenesis mainly through (i) abolishing
the surface abundance of c-fms and RANK receptors, and (ii) upregulating lysosomal activity,
subsequently augmenting the degradation of c-fms and RANK receptors, probably via the axis of
early endosomes–late endosomes–lysosomes in osteoclasts.
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1. Introduction
Osteoclasts, the bone-resorbing multinucleated cells, were primarily proliferated and differentiated
from mononuclear/macrophagic progenitors [1–3] via the mechanistic upregulation of c-fms and
RANK receptors by binding to M-CSF ligand and RANKL, respectively. RANKL binding to RANK
receptor activates nuclear factor of activated T cell cytoplasmic-1 (NFATc-1) [4], which is subsequently
translocated into nuclei to promote transcriptionally specific genes prerequisite for bone resorption
such as tartrate-resistant acid phosphatase (TRAP), Cathepsin K, and matrix metalloproteinase9
(MMP9) [5–7].
The well-characterized superfamily of Ras GTPase proteins is functionally categorized into five
cardinal branches such as Ras, Rho/Rac, Arf, Ran, and Rab families. Among these, Rab family of
proteins including more than 60 members in human genome regulates a variety of critical steps of
membrane trafficking, comprising vesicle movement and transport along actin or tubulin networks,
and membrane fusion [8–11]. Among the Rab GTPases, Rab11 ubiquitously found in eukaryotic
cells has been known as a regulator of vesicular trafficking amongst subcellular vesicles, specifically
via recycling pathways [12–14]. In mammals, the Rab11 subfamily is structurally and functionally
composed of three isotypes Rab11A, Rab11B, and Rab11C, the latest of which is also known as
Rab25 [15]. Of these, Rab11A GTPase is ubiquitously expressed [16] whereas Rab11B and Rab25 are
found exclusively in brain, testis, heart [17], lung, kidney, and gastric tract [18].
Rab7, a small GTPase, enriched in late endosomes and predominantly localized in the perimeter
of the ruffled border, functionally served as a suppressor of osteoclast polarization, resulting in
abolishment of bone-resorbing activity [19]. Notably, one of our previous studies elucidated an
important role of Rab27A in directing delivery of lysosome-mediated organelles and surface receptors
modulating osteoclast multinucleation, causing the morphological change to osteoclasts [20]. Later,
we also revealed a novel role of Rab44 as a negative regulator of osteoclast differentiation primarily
via elevating intracellular Ca2+ level, inducing NFATc-1 activation [21]. To Rab11, several previous
reports have clarified Rab11A was spatiotemporally concentrated in the pericentriolar endosomal
recycling compartments (ERCs) where Rab11 regulated the transport of the recycling transferrin
receptor (TfR) [12], whereas Rab11B is localized apically in proximity to the pericentrosomal region
distinct from that of Rab11A in MDCK cells [12], suggesting that Rab11A plays a housekeeping role in
regulating intracellular pathways of protein transport and/or receptor recycling. Nonetheless, whether
Rab11A functionally contributes to cargo transport networks amongst cellular vesicles required for
regulation of osteoclast differentiation remains unclear.
As abovementioned, lysosomal functions are required for regulation of osteoclast-induced bone
resorption through accelerating the secretion of the specific enzymes such as Cathepsin K, TRAP, and
MMP9, essential for bone destruction. In this study, using chloroquine (CLQ), dynamically diffusing
into lysosomes and undergoing protonation, causing alkalinization of the lysosomal lumen, thereby
impairing lysosomal function [22], we did clarify a novel role of lysosomes in proteolytically degrading
c-fms and RANK proteins. Markedly, Rab11A overexpression accelerated the process of lysosomal
proteolysis of c-fms and RANK proteins in osteoclasts. Altogether, we speculate one potentiality that
Rab11A overexpression promotes lysosome-induced proteolysis of c-fms and RANK receptors mainly
through the axis of early endosomes–late endosomes–lysosomes in osteoclasts, causally triggering
declination of osteoclastogenesis, eventually stabilizing bone resorption phase.
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2. Materials and Methods
2.1. Antibodies and Reagents
Recombinant human soluble RANKL was isolated by the protocols as described previously [23].
M-CSF was purchased from Kyowa Hakko Kogyo (Tokyo, Japan). Rabbit polyclonal anti-cathepsin B
and D antibodies were purified as detailed previously [24]. The other antibodies were used in this study
as follows: rat monoclonal anti-LAMP1, (Cat. no. 553,792, BD Biosciences, NJ, USA), rabbit polyclonal
anti-c-fms (Cat. no. sc-692, Santa Cruz, CA, USA), monoclonal anti-c-fos (Cat. no. sc-166,940, Santa
Cruz, CA, USA), mouse monoclonal anti-NFATc-1 (Cat. no. sc-7294, Santa Cruz, CA, USA), mouse
monoclonal anti-RANK (NBP2-247-2, Novus Biologicals Europe, Abingdon, UK), rabbit polyclonal
anti-GFP (Green Fluorescent Protein) pAb (Medical and Biological Laboratories Co., LTD., Nagoya,
Japan), rabbit polyclonal anti-Rab11A (#2413, Cell Signaling, Danvers, MA, USA), rabbit monoclonal
anti-Rab5 (# 3547, Cell Signaling, Danvers, MA, USA) and anti-Rab7 (#9367, Cell Signaling, Danvers,
MA, USA), rabbit monoclonal anti-GAPDH (Cat. no. 2118S, Cell Signaling, Danvers, MA, USA).
2.2. Cell Culture
A murine monocytic (RAW-D) cell line that was obtained by Prof. Toshio Kukita (Kyushu
University, Japan) [25,26] was cultured in minimum essential mediumα (MEMα) (Wako Pure Chemicals,
Osaka, Japan) supplemented with 10% fetal bovine serum (FBS), penicillin (100 U/mL), and streptomycin
(100 mg/mL). RAW-D cell-derived osteoclasts were induced by RANKL (100–300 ng/mL). Bone
marrow-derived macrophages (BMMs) were isolated from the femurs and tibias of 5-week-old male
C57BL/6J mice purchased from SLC (Shimizu Laboratory, Japan) as described previously [27], and
cultured in MEMα containing M-CSF (50 ng/mL) at 37 ◦C in 5% CO2 overnight. All animal experiments
were performed according to the guidelines for the care and use of laboratory animals approved by
Okayama University and the Japanese Pharmacological Society (OKU-2018438). Floating cells were
collected and cultured on the new culture dishes with MEMα containing M-CSF (50 ng/mL). On day
3 of culture, the adherent cells were referred to as BMMs. The BMMs were refreshed with MEMα
supplemented with M-CSF (30 ng/mL) and RANKL (300 ng/mL), and subsequently cultured in the
designated time periods.
2.3. Western Blot Analysis (WB)
RAW-D cells were pretreated with RANKL over an indicated time course. Cell lysates were
obtained using RIPA buffer (50 mM Tris-HCl (pH 8.0), 1% Nonidet P-40, 0.5% sodium deoxycholate,
0.1% SDS, 150 mM NaCl, 1 mM PMSF) including proteinase inhibitor cocktail (Sigma-Aldrich Tokyo,
Japan). The protein concentrations were subsequently determined by BCA assay, according to the
manufacturer’s guidance (Thermo Pierce, Rockford, IL, USA). The cell lysates (15 µg) were run
on 10% SDS-PAGE electrophoresis gels. The proteins were then transferred to PVDF membranes.
The blots were blocked in Tris-buffered saline containing 0.05% Tween 20 and 3% skim milk for
1.5 h at room temperature (RT), subsequently probed with various antibodies (1/1000) at 4 ◦C
overnight. After washing membranes, the blots were washed and incubated with horseradish
peroxidase (HRP)-conjugate secondary antibodies (GE Healthcare). Blots were eventually detected
with ECL substrate (Millipore, Burlington, MA, USA). The immunoreactive bands were observed by
the ChemiDoc MP Imaging System (Bio-Rad, Hercules, CA, USA). The quantitative densitometric
analysis was performed using Image J.
2.4. Small Interfering RNA (siRNA)
The target sequences of murine control the nontargeting siRNA (Ctrl si) (Stealth RNAiTMsiRNA
Negative Control, Invitrogen, Carlsbad, CA, USA) and Rab11A-targeting siRNA (Rab11A si) (Invitrogen
Custom Primers, Invitrogen, Carlsbad, CA, USA) were GAAUUCAACCUAGAGAGCAAGAGUA and
GACAUCUGCUCUAGAUUCUACAAAU, respectively. RAW-D cells (2 × 105 cells) were seeded and
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grown in 35 mm culture dishes. The next day, 10 pmol of siRNA was used to transfect into RAW-D
cells and was done using Lipofectamine RNAiMAX™ transfection reagent (Invitrogen, Carlsbad, CA,
USA), according to the manufacturer’s instructions. On the 1st day of post-transfection, the cell dishes
were refreshed by MEMα media supplemented with RANKL. For Western blotting and TRAP staining,
the cells were harvested after 3 days of RANKL stimulation.
2.5. TRAP Staining
Cells were fixed with 4% paraformaldehyde (PFA) at RT for 60 min and incubated with
0.2% Triton X-100 in PBS at RT for 5 min. Cells were then stained with TRAP solution (0.01%
naphtol AS-MX phosphate disodium salt (Sigma-Aldrich, St. Louis, MO, USA), 0.06% fast red
violet LB salt (Sigma-Aldrich Tokyo, Japan), 50mM sodium tartrate, and 50mM sodium acetate
(pH 5.0)). TRAP-positive counted cells with three or over 10 nuclei in whole well were counted as
mature osteoclasts.
2.6. Bone Resorption Assay
The bone-resorbing activity of osteoclasts was examined using the Osteo Assay Stripwell Plate
(Corning, MA, USA) after stimulated with RANKL for 7 days. Osteoclasts were differentiated from
RAW-D cells or BMM cells by RANKL (500 ng/mL) stimulation. Images for bone resorption area and
nuclei counting were taken by using all-in-one type fluorescence microscope BZ-9000 (Keyence, Osaka,
Japan). Bone resorption area was measured using the Image J software.
2.7. Immunocytochemistry
Cells were seeded and grown on glass coverslips and fixed with 4.0% PFA in PBS for 1 h at RT.
After washing the cells by PBS, the fixed cells were permeabilized with 0.2% Tween-20 in PBS for 5 min.
The cells were incubated with 10% normal goat serum for 30 min and subsequently incubated overnight
at 4 ◦C with the primary antibodies. The cells were washed and stained with the secondary antibodies
such as Alexa Fluor 594 goat anti-rat IgG or Alexa Fluor 594 goat anti-rabbit IgG (Cell Signaling
Technology Danvers, MA, USA). Finally, nuclear staining with 4,6-diamidino-2-phenylindole (DAPI,
Invitrogen Carlsbad, CA, USA) was examined. The samples were visualized using a laser-scanning
confocal imaging system (LSM 780 META; Carl Zeiss, AG, Jena, Germany).
2.8. Retrovirus Construction and Expression of Mouse Rab11A
The experimental protocols of Retrovirus construction and Rab11A overexpression were performed
as described previously [21]. Briefly, the full-length cDNA of mouse Rab11A was generated by PCR
using cDNA derived from M-CSF and RANKL-stimulated BMMs for 72 h. The primers were used
for GFP forward: 5′-GGACGAGCTGTACAAGGGCACCCGCGACGACGAGTAC-3′, and reverse:
5′-CTACCCGGTAGAATTCTTAGATGTTCTGACAGCACTGC-3′; the cDNAs were amplified by using
PrimeSTAR GXL DNA polymerase (Takara, Tokyo) with 40 cycles at which denaturation at 94 ◦C for
10 s, annealing at 62 ◦C for 30 s, and extension at 72 ◦C for 3 min for each cycle. To generate GFP-Rab11A
fusion protein, the amplified fragments were fused with a linearized pMSCVpuro-GFP, which was
kindly provided by Prof. Kosei Ito (Nagasaki University, Nagasaki, Japan), using In-Fusion cloning kit
(Clontech, Mountain View, CA, USA). pMSCVpuro-GFP was also used as a control vector. GFP-alone
and/orGFP-Rab11A vector was transfected into HEK293T cells by employing the Lipofectamine
2000 (Life Technologies, Gaithersburg, MD, USA), according to the manufacturer’s guidance. After
incubating at 37 ◦C in 5% CO2 for 48 h, the supernatants containing viruses were collected and used
to infect to RAW-D cells. RAW-D cells expressing GFP or GFP-Rab11A were selected by puromycin
(5 µg/mL) in MEMα containing 10% FBS, and the medium was refreshed every 3 days. After 2 weeks
of culture, the puromycin-resistant cloned cells were obtained.
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2.9. Flow Cytometry Analysis
The osteoclasts derived from RAW-D cells were used after 2 days of RANKL stimulation. The cell
suspension (1 × 106 cells/100 µL) incubated with the primary antibodies diluted with PBS solution
containing 1% normal goat serum was put on ice for 40 min. After successive pre-incubation
of the samples with Fc Block (anti-mouse CD16/CD32 antibody, #101301, Biolegend, CA, USA),
specific antibodies against c-fms (anti-mouse CD115-PE-conjugated, #135505, Biolegend, CA, USA)
or RANK (anti-mouse CD265-PE-conjugated, #119805, Biolegend, CA, USA) or TfR (anti-mouse
CD71-PE-conjugated, #113807, Biolegend, CA, USA) or isotype control (rat IgG2a κ-PE-conjugated,
#400507, Biolegend, CA, USA) were reacted on ice for 10 min, flow cytometric analyses were carried
out using a MACSQuant 2.5 (Miltenyi Biotec, Tokyo, Japan).
2.10. Surface Biotinylation Assay
RAW-D cells (5 × 105 cells) were seeded and grown in 10 cm dishes for 3 days upon RANKL
stimulation. Cells were washed twice by PBS and subsequently incubated for 1 h at 4 ◦C with 3.0 mg/mL
Sulfo-NHS-SS-Biotin (Pierce) dissolved in DPBS+. Cell dishes were rinsed in 100 mM glycine (10 min,
3×), and subsequently in 20mM glycine (10 min, 3×), both in DPBS+. Cells were harvested and lysed
by the buffer LB3 containing 50 mM Tris/HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% (w/v) Triton
X-100, and protease inhibitor. The cell lysates were gently rotated for 1 h at 4 ◦C. The cell lysates
were rotated by a rotator overnight at 4 ◦C with 40 µL Ultra Link Immobilized NeutrAvidin protein
(Pierce). Followed by the incubation, beads were washed 1×with lysis buffer LB3, 2×with LB2 (LB3
not containing protease inhibitor), 2× with SWS containing 0.1% Triton X-100 in PBS (pH 7.4), 350 mM
NaCl and 1 mM EDTA, and 1× with LB1 (LB2 not containing 1% (w/v) Triton X-100). Then, the beads
were completely mixed with 6× sample loading buffer and boiled for 5 min before being loaded on
SDS-PAGE gels.
2.11. CellTiter-Glo Viability Assay (CTG)
Cytotoxicity evaluation was carried out using the CellTiter-Glo Lyminescent Cell Viability Assay
Kit (Promega, Madison, WI, USA), according to the manufacturer’s instructions. In total, 5 × 103
cells/well were seeded and grown in 96-well white flat-bottomed plates. The plates were incubated at
37 ◦C in 5% CO2 for 24h before RANKL (300 ng/mL) addition. The plates were incubated for 3 days in
5% CO2, then simultaneously added with cyclohexamide (CHX) (20 µg/mL) and with or without CLQ
(10 µM) to each well, and subsequently incubated for another 3 h before quenched with CellTiter-Glo®
(Promega, Madison, WI, USA, 50 µL/well), then centrifuged at 1000 rpm for 1 min and incubated at RT
for 15 min. Luminescence was recorded with a plate reader (Molecular Devices, San Jose, CA, USA).
2.12. Statistical Analysis
Statistical significance was calculated using JMP Pro 15 and Microsoft Excel. Three or more mean
values were compared using one-way analysis of variance (ANOVA), while comparisons of two were
done with an unpaired Student’s t-test. p < 0.05 was considered to indicate statistical significance.
Data were expressed as mean ± SD.
3. Results
3.1. Rab11A is Upregulated at a Late Stage of Osteoclast Differentiation
To investigate whether Rab11A was involved in osteoclastogenesis, we firstly assessed the
homeostatic modification of Rab11A and two key transcription factors, c-fos and NFATc-1, essential for
osteoclast differentiation [4], over a time course of RANKL stimulation. Our data showed that the
endogenous levels of c-fos and NFATc-1 were transiently increased on day 1 and drastically decreased on
day 3 whereas that of Rab11A was significantly increased on days 3 and 4 in RAW-D cells (Figure 1A,C)
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and BMMs (Figure 1B,D). More importantly, by TRAP staining, we observed that the mature osteoclasts
were formed from day 3 in RAW-D cells (Figure 1E) and BMM cells (Figure 1F). Together, these results
indicate that Rab11A is strongly increased at a late stage of osteoclast differentiation.
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3.2. Rab11A Silencing Promotes Osteoclast Differentiation
To investigate if Rab11A was functionally involved in osteoclast differentiation, we first examined
the effect of siRNA-mediated Rab11A silencing on osteoclast differentiation. The siRNA-induced
knockdown efficacy of Rab11A was assessed by RT-qPCR and WB on days 0 and 3 of RANKL
stimulation. On day 0, our results showed the remarkable reductions of Rab11A mRNA and protein
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levels by 99.5% and by ≈80%, respectively (Figure 2A,C), and on day 3 of RANKL treatment, by 82%
and ≈ 90%, respectively (Figure 2B,D), as compared to the Ctrl si-treated groups. In TRAP staining, we
observed that Rab11A silencing markedly promoted the formation of multinucleated cells (MNCs) in
size and number in RAW-D-derived osteoclasts (Figure 2E–G) as well as BMM-derived osteoclasts
(Figure 3A–C). Noticeably, after assessing and comparing the bone resorption area, the Rab11A-silenced
osteoclasts derived from BMMs exhibited a considerable elevation in the bone-resorbing activity in
comparison with that of control group (Figure 3D,E). Altogether, these findings strongly indicate a
stimulatory effect of Rab11A silencing on osteoclast differentiation.
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Figure 2. The effects of Rab11A silencing on osteoclast differentiation. (A) RAW-D cells were
transfected with nontargeting (Ctrl) or Rab11A-specific siRNA for 24 h without RANKL stimulation.
The knockdown efficacy of Rab11A mRNA was analyzed by qRT-PCR. (B) RAW-D cells were transfected
with Ctrl si or Rab11A si for 24 h, followed by RANKL stimulation for 3 days. The knockdown efficacy
of Rab11A mRNA levels was analyzed by RT-qPCR. (C,D) Upper: The endogenous level of Rab11A
protei was assessed by WB on day 0 (C) and day 3 (D). Lower: Column scatter pl tting t compare
Rab11A protein level n day 0 (C) and day 3 (D). (E) TRAP staining of Ctrl si or R b11A si-treated
osteoclasts. The cells were treated with Ctrl si or Rab11A si 24 h, followed by RANKL stimulation for
3 days. An arrowhead indicated the mature osteoclasts. Scale bars: 200 µm. (F,G) The number of
TRAP-positive osteoclasts with 3–10 nuclei (F), or with more than 10 nuclei (G) per viewing field was
counted. * p < 0.05, ** p < 0.01, n = 3. Data are the representative of three independent experiments.
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Figure 3. The effects of Rab11A silencing on BMM-derived osteoclast differentiation. (A) Upper: BMM
cells were transfected with nontargeting siRNA (Ctrl si) or Rab11A-specific siRNA (Rab11A si) for 24 h
without RANKL stimulation. Lower: Column scatter plotting to compare Rab11A protein level. (B)
Upper: BMM cells were transfected with Ctrl siRNA or Rab11A siRNA for 24 h, followed by RANKL
stimulation for 3 days. The endogenous level of Rab11A protein was evaluated by Western blotting.
Lower: Column scatter plotting to compare Rab11A protein level. (C) TRAP staining of osteoclast
transfected Ctrl si or Rab11A si. Arrowheads showed large osteoclasts. Bars: 200 µm. (D) Images of the
bone resorption area of BMM-derived osteoclasts transfected with Ctrl si or Rab11A si. Bars: 100 µm.
(E) The resorption area was determined using Image J software. The data are represented as mean ±
SD of values from three independent experiments. * p < 0.05, compared to control cells.
3.3. Rab11A Overexpression Attenuates Osteoclast Differentiation
In order to fully understand the regulatory function of Rab11A on osteoclast differentiation,
we next sought to assess the effects of Rab11A overexpression on osteoclast differentiation by using
RAW-D cells stably expressing GFP or GFP-Rab11A, referred to as control or Rab11A overexpression,
respectively. Initially, we confirmed the expression of GFP and GFP-Rab11A (Figure 4A) in RAW-D
cells cloned by puromycin selection by WB analysis. We next evaluated the formation of osteoclasts
expressing GFP or GFP-Rab11A by TRAP staining. Our data showed that Rab11A overexpression
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strongly attenuated the formation of MNCs in size as well as in number (Figure 4B–D). Importantly,
Rab11A-overexpressing osteoclasts exhibited a marked reduction in the bone-resorbing activity as
compared to that of control group (Figure 4E,F). Taken together, our results suggest an inhibitory
function of Rab11A overexpression on osteoclast differentiation.
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Figure 4. The effect of Rab11A overexpression on osteoclastogenesis. (A) GFP or GFP-Rab11A
expression was determined in RAW-D cells transduced with either retrovirus vector encoding GFP or
GFP-tagged Rab11A (GFP-Rab11A). An “asterisk” indicated the GFP-Rab11A band. (B) TRAP staining
of GFP and GFP-Rab11A-expressing osteoclasts derived from RAW-D cells. Arrowheads showed
mature osteoclasts. Scale bars: 200 µm. (C,D) The number of TRAP-positive multinucleated osteoclasts
with 3–10 nuclei or more than 10 nuclei per viewing field was counted. ** p < 0.01. (E) Images of the
bone resorption area of RAW-D-derived osteoclasts expressing GFP-alone or GFP- Rab11A. Scale bars:
100 µm. (F) The resorption area was determined using Image J software. The data are represented as
mean ± SD of values from three independent experiments.
3.4. Rab11A is Localized in Early and Late Endosomes, but not Lysosomes, and Rab11A Overexpression
Triggered a Size-Based Enlargement of Early Endosomes
Previously it has been shown that Rab11A is predominantly enriched in ERCs and crucial for the
regulation of the recycling of endocytosed cargos inclu ing cell surface receptors such as TfR [12,28].
Therefore, we examined the col calization of GFP-Rab11A with several organelles-specific markers
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including Rab5 (early endosomes), Rab7 (late endosomes), and LAMP1 (lysosomes). Our results
showed that Rab11A was localized in early and late endosomes, but not lysosomes in RAW-D cells
(Figure 5A, arrowheads) and RAW-D-derived osteoclasts (Figure 5B, arrowheads). Furthermore, we
observed that Rab11A overexpression caused the enhanced fluorescent intensity and a size-based
enlargement of early endosomes in RAW-D cells (Figure S1), suggesting that Rab11A was engaged in
regulation of accumulation of internalized cargos in early endosomes. Collectively, our data clearly
indicate Rab11A vesicular localization in early and late endosomes, but not lysosomes.
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Figure 5. Subcellular localization of Rab11A in RAW-D cells and RAW-D cell-derived osteoclasts
expressing GFP-Rab11A (green). (A,B) RAW-D cells (A) or osteoclasts following RANKL stimulation
for 3 days (B) were seeded on cover glasses, permeabilized with 0.2% Triton X-100 diluted in PBS,
subsequently reacted with one of the antibodies against Rab5, Rab7, or LAMP1 (red, as indicated).
DNA was stained with DAPI (blue). Arrowheads indicated the positive region of GFP-Rab11A and
each organelles-specific markers. Scale bars: 5 µm. The images shown were the representative of three
independent experiments.
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3.5. Rab11A Silencing Upregulated the Surface Levels of c-fms and RANK Receptors
To elucidate the mechanism by which Rab11A negatively regulates osteoclast differentiation,
we examined the endogenous levels of c-fms, RANK, and NFATc1 in Rab11A-silenced RAW-D cells
stimulated with RANKL for 0 or 3 days. Our results showed Rab11A silencing markedly increased the
endogenous levels of c-fms, RANK, and NFATc-1 proteins in RAW-D cells stimulated with RANKL
for 0 day (Figure 6A–C, left panels) and for 3 days (Figure 6A–C, right panels). The same effects
were also observable in BMMs (Figure 6B–D). Next, we examined if Rab11A silencing affected the
surface levels of c-fms and RANK receptors by surface biotinylation assay. Interestingly, we found that
Rab11A silencing markedly elevated their surface levels in RAW-D cells, following RANKL stimulation
for 3 days (Figure 6E). In combination with our above findings (Figures 2 and 3), our results clearly
substantiate an inhibitory effect of Rab11A on osteoclast differentiation mainly via enhancing the
surface abundance of c-fms and RANK receptors.
Cells 2020, 9, x FOR PEER REVIEW 11 of 19 
 
3.5. Rab11A Silencing Upregulated the Surface Levels of c-fms and RANK Receptors 
To elucidate the mechanism by which Rab11A negatively regulates osteoclast differentiation, we 
examined the endogenous levels of c-fms, RANK, and NFATc1 in Rab11A-silenced RAW-D cells 
stimulated with RANKL for 0 or 3 days. Our results showed Rab11A silencing markedly increased 
the endogenous levels of c-fms, RANK, and NFATc-1 proteins in RAW-D cells stimulated with 
RANKL for 0 day (Figure 6A–C, left panels) and for 3 days (Figure 6A–C, right panels). The same 
effects were also observable in BMMs (Figure 6B–D). Next, we examined if Rab11A silencing affected 
the surface levels of c-fms and RANK receptors by surface biotinylation assay. Interestingly, we 
found that Rab11A silencing markedly elevated their surface levels in RAW-D cells, following 
RANKL stimulation for 3 days (Figure 6E). In combination with our above findings (Figures 2 and 
3), our results clearly substantiate an inhibitory effect of Rab11A on osteoclast differentiation mainly 
via enhancing the surface abundance of c-fms and RANK receptors.  
A previous study revealed a crucial role of Rab11A in regulating the trafficking of TfR to surface 
membrane in the polarized cells [12]. We therefore tested TfR as an indicator to investigate the 
transport route of Rab11A silencing-mediated c-fms and RANK receptors by flow cytometric assay. 
Surprisingly, we observed that Rab11A silencing markedly decreased surface level of TfR in RAW-D 
cells stimulated with RANKL for 2 days (Figure 6F). These results indicate that the Rab11A is 
obviously engaged in regulating the transport route of c-fms and RANK receptors, probably distinct 
from that of TfR.  
 
0
1
2
3
c-fms RANK NFATc1
Ctrl s i Rab11A si
0
1
2
3
c-fms RANK NFATc1
Ctrl s i Rab11A si
Fig. 5
A
Day 0
Ctrl
si
Rab11A
si
Day 3
Ctrl
si
Rab11A
si
c-fms
RANK
NFATc1
GAPDH
RAW-D
B
-75
-100
-50
-150
-250
-75
-100
-50
-150
-250
Day 0
Ctrl
si
Rab11A
si
Day 3
Ctrl
si
Rab11A
si
BMM
C D
c-fms
RANK
NFATc1
GAPDH
F
+ RANKL
(3 days)
E
0
1
10-1 1 10 102 103
PE/PI-A
R
e
la
ti
v
e
 C
e
ll 
N
u
m
b
e
r
Ctrl si
Rab11A si
Rat IgG2a k
TfRRAW-D
Ctrl
si
Rab11A
si
biotinylated 
fractions
c-fms
GAPDH
RANK
c
-f
m
s
/G
A
P
D
H
R
A
N
K
/G
A
P
D
H
Day 0 Day 3
0
4
8
12
c-fms RANK NFATc1
Ctrl s i Rab11A si
0
1
2
3
c-fms RANK NFATc1
Ctrl s i Rab11A si
R
e
la
ti
v
e
 
e
x
p
re
s
s
io
n
 l
e
v
e
ls
Day 0 Day 3
R
e
la
ti
v
e
 
e
x
p
re
s
s
io
n
 l
e
v
e
ls
0
1
2
3
Ctr l si 11A si
0
1
2
3
Ctr l si 11A si
Figure 6. The effects of Rab11A silencing on cell surface levels of c-fms and RANK receptors in RAW-D
cells stimulated with RANKL (300 ng/mL). (A) The endogenous levels of c-fms, RANK, and NFATc1
in Ctrl or Rab11A si-treated RAW-D cells stimulated with RANKL for 0 (left panels) or 3 days (right
panels). (B) The endogenous levels of c-fms, RANK and NFATc1 in Ctrl or Rab11A si-treated BMMs
stimulated with RANKL for 0 (left panels) or 3 days (right panels). (C,D) Quantitative analyses of
Western blot for c-fms, RANK, NFATc1, in RAW-D cells (C) or BMMs (D). GAPDH was used as an
internal control. * p < 0.05. (E) Upper: The biotinylated fractions were subjected to immunoblotting
Cells 2020, 9, 2384 12 of 19
with anti-mouse c-fms and anti-mouse RANK antibodies, and whole cell lysates (WCLs) were subjected
to immunoblotting with anti-GAPDH antibody as a loading control in RAW-D cells following RANKL
stimulation for 3 days. Lower: Quantitative analyses of Western blot for c-fms, RANK. * p < 0.05. (F)
Flow cytometric analyses of TfR using Ctrl or Rab11A siRNA-transfected RAW-D cells, followed by
RANKL stimulation for 2 days. Data are representative of three independent experiments.
A previous study revealed a crucial role of Rab11A in regulating the trafficking of TfR to surface
membrane in the polarized cells [12]. We therefore tested TfR as an indicator to investigate the transport
route of Rab11A silencing-mediated c-fms and RANK receptors by flow cytometric assay. Surprisingly,
we observed that Rab11A silencing markedly decreased surface level of TfR in RAW-D cells stimulated
with RANKL for 2 days (Figure 6F). These results indicate that the Rab11A is obviously engaged in
regulating the transport route of c-fms and RANK receptors, probably distinct from that of TfR.
3.6. Rab11A Overexpression Downregulated Surface Levels of c-fms and RANK Receptors in Osteoclasts
Next, we examined the mechanistic effects of Rab11A overexpression on regulation of surface
levels of c-fms and RANK receptors in RAW-D cell-derived osteoclasts. Consistently, our results showed
that Rab11A overexpression strongly decreased the endogenous levels of c-fms, RANK, and NFATc-1
in RAW-D cells stimulated with RANKL for 0 or 3 days (Figure 7A,B); more importantly, abolishing the
surface levels of c-fms and RANK receptors in RAW-D cells following RANKL stimulation for 3 days
(Figure 7C). Besides, the surface level of TfR was slightly altered by Rab11A overexpression in RAW-D
cells stimulated with RANKL for 2 days (Figure 7D). These data further clarify (i) a suppressive role
of Rab11A overexpression on osteoclast differentiation through weakening the surface abundance of
c-fms and RANK receptors and suggest that (ii) Rab11A overexpression-mediated transport route of
c-fms and RANK receptors distinct from that of TfR.
3.7. Rab11A Overexpression Facilitated Lysosome-Induced Degradation of c-fms and RANK Receptors in
RAW-D Cell-Derived Osteoclasts
So far, it has been well-characterized that lysosome-degraded surface receptors are processed from
early endosomes to late endosomes before transported to lysosomes for proteolysis [29–31]. As above
(Figure 5), we observed the vesicular localization of Rab11A in early and late endosomes, we therefore
hypothesized that Rab11A might have functionally engaged in the early and late endosome-mediated
delivery of c-fms and RANK surface receptors to lysosomes in osteoclasts. To address this hypothesis,
we first examined the effects of Rab11A overexpression on lysosomal activity by assessing the
expression levels of the lysosomal marker, LAMP1 and two major lysosomal enzymes, Cathepsins
B and D. By Rab11A overexpression, the endogenous levels of LAMP1, Cathepsins B and D were
insignificantly altered with RANKL stimulation for 0 days while strongly increased with RANKL
stimulation for 3 days (Figure 8A,B), suggesting a functional connection of Rab11A overexpression to
augmentation of lysosomal activity in osteoclasts. Next, we used CLQ, a specific blocker of lysosomes,
and CHX, a specific blocker of newly protein synthesis, to investigate if lysosomes were engaged
in Rab11A-mediated regulation of c-fms and RANK protein. Surprisingly, it was observable that
lysosomal inhibition enhanced the endogenous levels of c-fms and RANK protein (Figure 8C,D),
regardless of Rab11A overexpression, suggesting that lysosomes functionally contributed to proteolytic
degradation of c-fms and RANK proteins in osteoclasts. More interestingly, Rab11A overexpression also
triggered lysosome-induced degradation of c-fms and RANK (Figure 8C,D). There was no significant
toxic effect observed in all the cases treated (Figure 8E). These findings elucidate an important function
of lysosomes on proteolytically degrading c-fms and RANK surface receptors, and this process would
be facilitated by Rab11A overexpression in osteoclasts, thereby weakening osteoclast differentiation.
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Figure 7. The effects of Rab11A overexpression on cell surface levels of c-fms and RANK receptors in
RAW-D cells upon RANKL stimulation. (A) The endogenous levels of c-fms, RANK, and NFATc1 in
RAW-D cells expressing GFP (control) or GFP- Rab11A following RANKL stimulation for 0 or 3 days.
(B) Quantitative analyses of Western blot for c-fms, RANK, NFATc1. GAPDH was used as an internal
control. * p < 0.05. (C) Upper: The biotinylated fractions were subjected to immunoblotting with
anti-mouse c-fms and anti-mouse RANK antibodies, and WCLs were subjected to immunoblotting with
GAPDH-HRP antibody as a loading control in RAW-D cells expressing GFP (control) or GFP-Rab11A.
Lower: Quantitative analyses of Western blot for c-fms, RANK. (D) Flow cytometric analyses of TfR
were done using RAW-D cells expressing GFP (control) or GFP-Rab11A. Data are the representative of
three independent experiments.
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Figure 8. The lysosomal function on c-fms and RANK protein degradation ameliorated by
Rab11A overexpression in RAW-D cell-derived osteoclasts. (A) The endogenous levels of LAMP1
(a specific lysosomal receptor), and Cathepsins B and D (two major lysosomal enzymes) in GFP or
GFP-Rab11A-expressing RAW-D cells following RANKL stimulation for 0 (left panel) or 3 days (right
panel) were analyzed by WB with anti-rat LAMP1, anti-rabbit Cathepsins B and D, and GAPDH-HRP
(loading control). (B) Quantitative analyses of Western blot for LAMP1, Cathepsin B, Cathepsin D.
GAPDH was used as an internal control. * p < 0.05. (C) After 3 days of RANKL (300 ng/mL) stimulation,
RAW-D cell-derived osteoclasts were treated simultaneously with 20 µg/mL CHX and with or without
10 µM CLQ for 3 h. c-fms and RANK protein levels were assessed by WB with anti-mouse c-fms,
anti-mouse RANK, and GAPDH-HRP (loading control) antibodies. (D) Quantitative analyses of
Western blot for c-fms and RANK. GAPDH was used as an internal control. * p < 0.05. (E) Cell viability
was assessed by the cellular ATP content measurement using the CTG Assay system. After stimulated
with RANKL (300 ng/mL) for 3 days, RAW-D cells were subsequently added with 20 µg/mL CHX and
with or without 10 µM CLQ for 3 h. The values were the average of triplicate determinations with the
S.D indicated by error bars. n.s; no significant.
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4. Discussion
Rab GTPase proteins are localized in various intracellular compartments, including endosomes,
Golgi complex, lysosomes, and the cell surface. The Rab GTPases are master regulators of distinct steps
of intracellular vesicle transport, protein trafficking, membrane targeting, and fusion in eukaryotic
cells [32]. In principle, Rab GTPase proteins are thought to be functionally interconnected to one another
to regulate cargo transport routes through intracellular compartments [33], such as from recycling
endosomes to cell surface and/or to cytosolic organelles in various cell types, functions especially
active in cancer cells [34]. In our current study, we initially found Rab11A was upregulated as mature
osteoclasts were formed (Figure 1), conjecturing that Rab11A possibly served as a negative regulator of
osteoclastogenesis. Indeed, Rab11A silencing strongly promoted osteoclast formation, bone-resorbing
activity, augmented surface levels of c-fms and RANK receptors, resulting in NFATc-1 upregulation in
both osteoclasts derived from RAW-D cells (Figure 2E–G) and BMMs (Figure 3C–E). Besides, Rab11A
overexpression reduced such characteristics in RAW-D cell-derived osteoclasts (Figure 4B–F). From
these findings, it was clarified an inhibitory role of Rab11A for regulation of osteoclastogenesis. Though
our bone resorption data indicated the bone-resorbing activity of osteoclasts derived from both RAW-D
cells and/or BMMs, it would be noteworthy of examining the other factors such as actin ring formation,
Cathepsin K (CTSK), DC (or OC)-STAMP, and/or ATPase, H+ transporting, lysosomal pump (atp6v0d2)
expression, in order to fully understand the physiological role of Rab11A in osteoclast differentiation
regulation. Therefore, it would be probably one of our future research goals.
The vesicular cellular localization of Rab11A was observed in early and late endosomes in both
premature (Figure 5A) and mature (Figure 5B) osteoclasts, and Rab11A overexpression caused the
enhanced fluorescent intensity and the size-based enlargement of early endosomes in RAW-D cells
(Figure S1A,B). Interestingly, our previous report also showed the same effects of Rab44 on enlarging
early endosomes in RAW-D cells [21]. From these observations, we therefore proposed one possibility
that Rab11A overexpression promoted the accumulation of the internalized cargos including the surface
receptors, in early endosomes though this phenomenal consequence has been obscure, and needs to be
further investigated. Of note, an earlier report has revealed endogenous depletion of Rab11A caused
the enlargement of early endosomes, and augmentation of late endosomal and lysosomal activities in
nonpolarized HeLa cells [35], suggesting a functional complexity of Rab11A in human cells.
So far, there have been two endosomal recycling pathways, comprising fast and slow recycling
routes, in which TfR receptor was elucidated to recycle to the cell surface exclusively via the slow
recycling route [12]. As described herein, Rab11A silencing strengthened the surface levels of c-fms and
RANK receptors (Figure 6E) while inhibiting that of TfR (Figure 6F). Reversely, Rab11A overexpression
decreased the cell surface levels of c-fms and RANK receptors (Figure 7C) while slightly increasing
that of TfR receptor (Figure 7D). Based on these observations, we proposed that Rab11A-mediated
transport route of c-fms and RANK surface receptors is distinct from that of TfR. By the method of
exclusion, we hypothesized that c-fms and RANK surface receptors might have been recycled to surface
membrane through the fast recycling route. On the contrary, the surface levels of c-fms and RANK
receptors were markedly decreased with respect to Rab11A overexpression in RAW-D cell-derived
osteoclasts (Figure 7C), suggesting that the Rab11A-mediated transport route of c-fms and RANK
surface receptors was not through the fast recycling route. On the emphasis of the functional importance
of lysosomes in regulating proteolysis of cellular cargos such as surface receptors via the axis of early
endosome–late endosomes–lysosomes, it prompted us to examine if Rab11A overexpression might
have been associated with lysosomal activity. Indeed, Rab11A overexpression markedly surged the
lysosomal activity through upregulation of LAMP1, and Cathepsins B and D in osteoclasts (Figure 8A).
Intriguingly, using a specific blocker of lysosomes, CLQ, we found that lysosomal inhibition elevated
the endogenous levels of c-fms and RANK proteins (Figure 8C,D), regardless of Rab11A overexpression,
upon RANKL stimulation, suggesting a natural characteristic of lysosomes degrading c-fms and RANK
proteins in osteoclasts. Additionally, the same effects were found in Rab11A-overexpressing RAW-D
cell-derived osteoclasts (Figure 8C,D).
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Our study touches upon a Rab11A-specific mechanism on potential bone resorption protection.
An early report did clarify the function of Rab11 on regulating the surface proteins, comprising
the surface receptors [36]. Intriguingly, we unmasked a regulatory role of Rab11A silencing in
osteoclastogenesis via limiting the cell surface levels of c-fms and RANK receptors both of which
are prerequisite for osteoclast differentiation (Figure 6). Besides, our earlier report obviously
disclosed the functional roles of Rab27A as the negative modulator of osteoclast differentiation,
using Rab27A-deficient Ashen mice [20]. The osteoclasts originating from these mice were much bigger
in size than those from of the wild-type counterparts, of note, similar effects were also observable
by Rab11A silencing in the RAW-D cell-derived osteoclasts. In addition to the abovementioned
effect of Rab27A on osteoclast differentiation, it was clear Rab27A was identified to regulate the
transport of lysosomal system-related organelles to the ruffled border in collaboration with Rab7 [37],
thereby suggesting an inhibitory effect of the bone resorption activity in Rab27-deficient osteoclasts.
Furthermore, one of the Rab family proteins, Rab44, was functionally elucidated to be a suppressive
modulator of osteoclast differentiation via effecting on the intracellular Ca2+ level, thereby modulating
NFATc1 signaling cascades [21]. Structurally, Rab44 is an atypical Rab-GTPase containing several
additional domains such as the EF-hand domain, coiled-coil domain, and the Rab-GTPase domain as
well [38]. Of which, EF-hand domain highly conserved in vertebrates such as human, mouse, and rat,
was the regulator of intracellular Ca2+ level. Nonetheless, although Rab11A, a typical Rab-GTPase
lacking in the EF-hand domain, was thought to not be involved in Ca2+ oscillation, it should be
further investigated.
5. Conclusions
Our study revealed a novel role of Rab11A serving as a negative regulator of osteoclast
differentiation mainly via weakening the surface abundance of c-fms and RANK receptors, whose
activation results in upregulating NFATc1 signaling cascades, thereby inducing osteoclast differentiation.
More intriguingly, our study was also the first report reflecting one another function of lysosomes on
proteolytically degrading c-fms and RANK receptors in osteoclasts, causally resulting in abolishing
osteoclast differentiation. Altogether, our novel findings extend our knowledge of the regulatory
mechanisms of osteoclast characteristics and bone physiology, probably facilitating development of
establishment of the new therapeutic drugs effective to the treatments of both inflammation-caused
bone loss and macrophage-triggered inflammatory syndromes.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/9/11/2384/s1,
S1. Figure S1. Comparison of Rab5 expression between GFP and GFP-Rab11A overexpress RAW-D cells. (A)
Representative images of Rab5 expression (red) with the same exposure time. DNA was stained with DAPI (blue).
Arrowheads indicated the positive region of Rab5. Scale bars 5 µm. (B) The expression area divided by the number
of cells in the field was quantified and measured by ImageJ software. ** p < 0.01. Data are representative of three
independent experiments.
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Abbreviations
BMMs bone marrow-derived macrophages
GFP green fluorescent protein
ERC endosomal recycling compartment
LAMP1 lysosomal associated membrane protein 1
M-CSF macrophage colony-stimulating factor
MMP9 matrix metalloproteinase
NFATc-1 nuclear factor of activated T-cells c1
RANK receptor activator of nuclear factor-κB
RANKL RANK ligand
TfR transferrin receptor
TRAP tartrate-resistant acid phosphatase.
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